Asieris Pharmaceuticals Enters an Exclusive Licensing Agreement with Theramex for CEVIRA® subject to certain conditions, Advancing the Global Development and Commercialization of a Non-Surgical Treatment for Cervical Precancerous Lesions in Europe

Agreement is expected to grant Theramex exclusive rights to CEVIRA® in Europe, Australia, New Zealand and Turkey, while Asieris retains rights for the rest of the world. The deal includes 15 million US dollars of upfront payment and a total of 11 million dollars of near-term regulatory...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.